Would you live on Vaccine Avenue or Virology Grove?
Ashlar Village is on the site of the former Ruchill Hospital, which closed in 1998.
Now the development of over 400 homes will feature Vaccine Drive, Virology Grove, Radiography Road and Laboratory Place.
The Glasgow MSP Paul Sweeney backed the names and told the BBC it was in tribute to the work at the hospital in the past.
Speaking to the Jeremy Vine Show, he explained his original suggestion was to acknowledge "key pioneers" at the hospital, which was originally built to deal with infectious disease.
He explained: "The council said that since Black Lives Matter and controversies over naming streets after people, we have decided no longer to name streets after persons alive or dead - so it would need to be something more abstract.
"I head-scratched and thought 'let's make it more particular to the function of the hospital' - obviously it's tricky to name something Tuberculosis Terrace so I tried to keep them appropriately named."
Social media reaction has been mixed, with some comments calling them "crazy" and others cracking jokes.
However Sweeney believes the choices serve as an acknowledgment of the history in the area, even if he admits some of that past was "unpleasant", including the hospital dealing with the Aids pandemic in the 1980s.
He said: "It's a very important social history and it's trying to credit some of the work done there, but perhaps in a more oblique way than first intended."
Not all of his ideas made the cut though - X-Ray Drive was rejected due to a hyphen being in it, which forced the change to Radiography Road.
Some neighbouring streets are, however, named in honour of the architect who designed the old hospital - Alexander McDonald.
The new development will feature one, two three and four bedroom homes with a garage or parking space, which Sweeney says will help an area that has consistently suffered from "a chronic lack of homes".
A spokeswoman for Glasgow City Council said that naming conventions for Glasgow streets have been in place since the late 1980s, basing them around "the history of the site in question."
She added "After a series of discussions on an initial list of proposed names, and in keeping with the street naming convention - whereby street names are given using the history of the site in question - the local elected members felt that these names fitted given the former hospital on site was famous for its remarkable work with infectious diseases."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Abbott, Siemens Healthineers, and Thermo Fisher Scientific Lead the Market with Innovative Portfolios and Strategic Expansion
The HIV Diagnostics Companies Quadrant report offers an in-depth analysis of the global HIV diagnostics market, assessing over 100 companies and highlighting the Top 14 leaders. Market expansion is driven by rising HIV/AIDS prevalence, point-of-care technological advancements, and awareness campaigns. However, high costs and skilled technician shortages hinder growth. North America leads in market dominance due to its HIV/AIDS prevalence and advanced technologies, while Asia Pacific is projected to grow fastest. Key players like Abbott, Siemens Healthineers, and Thermo Fisher Scientific employ strategies like acquisitions and innovations to maintain strong market positions amid evolving trends. Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "HIV Diagnostics - Company Evaluation Report, 2025" report has been added to HIV Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for HIV Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. 360 Quadrants evaluated over 100 companies, of which the Top 14 HIV Diagnostics Companies were categorized and recognized as the quadrant growth can be attributed to the rising prevalence of HIV/AIDS, the advantages offered by point-of-care instruments & kits, and increasing initiatives for HIV awareness campaigns. However, the high cost of NATs, operational barriers, and the shortage of skilled laboratory technicians are key factors restraining the market growth. The high growth potential of emerging economies and the trend of self-testing are expected to provide lucrative opportunities for market players during the forecast HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominated the global market in 2023. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North the Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this Players:Key players in this market include Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland). These players adopt various strategies, such as product launches, expansions, acquisitions, and collaborations, to excel in this (US)Abbott is a leading player in the HIV diagnostics market, known for its impactful Company Product Portfolio that includes FDA- and CE-approved products. The company's strong Company Market Share in the U.S. is complemented by its strategic focus on expanding its presence in emerging markets through varied Company Positioning strategies. By leveraging inorganic growth strategies, such as collaborations and acquisitions, Abbott aims to bolster its Company Healthineers AG (Germany)Siemens Healthineers is a cornerstone in the HIV diagnostics sphere, providing a broad array of medical solutions. Their focus on organic strategies and innovation has allowed them to maintain a competitive Company Positioning. With a significant presence in Europe, America, and emerging markets, they continue to excel in Company Market Share by offering innovative products that meet health sector Fisher Scientific (US)With a comprehensive Company Product Portfolio that spans PCR-based assays and immunoassays, Thermo Fisher Scientific remains a leader. Their strategies focus on regulatory approvals and strategic acquisitions to enhance their Company Market Share. Through collaboration with healthcare organizations, they aim to boost early HIV detection and improve global health access, effectively securing their Company Positioning and Company Ranking in the Topics Covered: 1 Introduction1.1 Market Definition1.2 Inclusions & Exclusions1.3 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Rising Prevalence of Hiv/Aids3.2.1.2 Increasing Number of Blood Transfusions & Blood Donations3.2.1.3 Advantages Offered by Poc Diagnostic Kits & Instruments3.2.1.4 Increasing Initiatives for Hiv Awareness Campaigns3.2.2 Restraints3.2.2.1 High Cost of Nats3.2.3 Opportunities3.2.3.1 High Growth Potential of Emerging Economies3.2.3.2 Trend of Self-Testing and Growing Preference for At-Home Diagnostic Kits3.2.4 Challenges3.2.4.1 Operational Barriers and Shortage of Skilled Laboratory Technicians3.3 Trends/Disruptions Impacting Customers' Businesses3.4 Value Chain Analysis3.5 Supply Chain Analysis3.6 Ecosystem Analysis3.7 Technology Analysis3.7.1 Key Technologies3.7.1.1 Elisa3.7.2 Complementary Technologies3.7.2.1 Western Blot Tests3.7.3 Adjacent Technologies3.7.3.1 Pcr3.8 Patent Analysis3.9 Key Conferences & Events, 2025-20263.10 Porter's Five Forces Analysis3.10.1 Threat of New Entrants3.10.2 Threat of Substitutes3.10.3 Bargaining Power of Buyers3.10.4 Bargaining Power of Suppliers3.10.5 Intensity of Competitive Rivalry3.11 Impact of Ai/Generative Ai on Hiv Diagnostics Market3.11.1 Market Potential of Ai in Hiv Diagnostics3.11.2 Ai Use Cases3.11.3 Company Implementation of Ai3.11.4 Future of Ai/Generative Ai4 Competitive Landscape4.1 Overview4.2 Key Player Strategies/Right to Win4.2.1 Overview of Strategies Adopted by Key Players in Hiv Diagnostics Market4.3 Revenue Analysis, 2021-20234.4 Market Share Analysis, 20234.4.1 Ranking of Key Market Players4.5 Company Evaluation Matrix: Key Players, 20234.5.1 Stars4.5.2 Emerging Leaders4.5.3 Pervasive Players4.5.4 Participants4.5.5 Company Footprint: Key Players, 20234.5.5.1 Company Footprint4.5.5.2 Region Footprint4.5.5.3 Product Footprint4.5.5.4 End-User Footprint4.6 Company Evaluation Matrix: Startups/Smes, 20234.6.1 Progressive Companies4.6.2 Responsive Companies4.6.3 Dynamic Companies4.6.4 Starting Blocks4.6.5 Competitive Benchmarking: Startups/Smes, 20234.6.5.1 Detailed List of Key Startups/Sme Players4.6.5.2 Competitive Benchmarking of Key Startups/Smes4.7 Company Valuation & Financial Metrics4.8 Brand/Product Comparison4.9 Competitive Scenario4.9.1 Product/Service Launches & Approvals4.9.2 Product Launches & Approvals4.9.3 Deals4.9.4 Expansions4.9.5 Other Developments5 Company Profiles Abbott Siemens Healthineers Grifols, S.A. Danaher Corporation Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. F. Hoffmann-La Roche Ltd. Biomerieux Hologic, Inc. Qiagen Bd Trinity Biotech Orasure Technologies, Inc. Biosynex Sa Wondfo Getein Biotech, Inc. Meril Life Sciences Pvt. Ltd. Accubiotech Co., Ltd. Biolytical Laboratories Inc. Bio Lab Diagnostics (I) Private Limited Alpine Biomedicals Pvt Ltd. Molbio Diagnostics Pvt. Ltd. Fortress Diagnostics Advacare Pharma (Accuquik) Adaltis S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
a day ago
- Fast Company
FDA warns one of summer's biggest viral beauty hits may not be safe
If your summer skincare looks more like dessert than SPF, the FDA has a message: put down the whipped cream canister — especially if it's actually sunscreen. On Monday, the agency dropped an unusually beachy buzzkill, warning that mousse-style sunscreens — the viral, fluffy-textured formulas all over TikTok — might not protect you as promised. Even worse? Their ice-cream-topping aesthetic could tempt someone to take a taste. And yes, that's as bad of an idea as it sounds. 'Beware of sunscreen products in mousse form because they might not be effective,' the agency wrote on X. 'Some mousse sunscreen products resemble whipped cream containers and may put consumers at risk if ingested.' The FDA's social media statement was accompanied by a flurry of official warnings issued to companies making mousse-style sunscreens, which have taken off thanks to TikTok trends and influencer campaigns. On TikTok, some videos joke about mousse sunscreen's resemblance to whipped cream by pretending to ingest it. Subscribe to the Daily newsletter. Fast Company's trending stories delivered to you every day Privacy Policy | Fast Company Newsletters The warnings were issued to five sunscreen companies: Supergoop, Vacation, TiZO, Kalani and K & Care Organics. Beware of sunscreen products in mousse form because they might not be effective. The FDA issued five warning letters to companies marketing sunscreen products in mousse form: — FDA Drug Information (@FDA_Drug_Info) August 12, 2025 In the letters, the FDA states that the brands' mousse sunscreens don't comply with its guidelines and haven't been approved to be marketed in mousse form. According to the FDA, sunscreens in forms 'other than oil, lotion, cream, gel, butter, paste, ointment, stick, spray, and powder' need an additional authorization to be marketed as effective sunscreen. 'As previously stated, there are no FDA-approved applications in effect for your drug products,' the agency states. The FDA gave the sunscreen brands 15 days to reply or pursue compliance with the concerns in the letter, which was dated back to August 6. The FDA went further with the viral mousse sunscreen brand Vacation, pointing to 'misbranding' concerns with some of the company's packaging. Vacation's Classic Whip sunscreen comes in a red and white canister that's designed to look almost exactly like a can of whipped cream – a marketing flourish that sent its mousse sunscreens viral. 'Specifically, your sunscreens are presented in metal canisters… that outputs a star-shaped foam and have a strong overall resemblance to the metal canisters ordinarily used to package whipped cream products and similar dessert toppings,' the FDA wrote, adding that selling products classified as drugs in food container lookalikes increases the risk of accidental ingestion. What's the deal with the mousse? While traditional lotion, stick and spray sunscreens have occupied drug store shelves for years, mousse-style sunscreens only exploded onto the scene recently. Accelerated by TikTok posts of influencers slathering themselves in what looks like Reddi-wip, Vacation quickly enjoyed its social media-powered moment in the sun. advertisement 'At Supergoop! we remain committed to innovation in sun care and the highest standards of product efficacy and safety,' the company told Fast Company in a statement. 'The recent communication from the FDA regarding our PLAY SPF 50 Body Mousse is focused on product labeling and has nothing to do with its safety, effectiveness, or formula. We are working closely with the FDA to resolve this matter as we continue to uphold the high standards our consumers expect from us.'
WebMD
2 days ago
- WebMD
Breakthroughs in HIV
It's been over 40 years since the emergence of HIV. It's killed hundreds of thousands of Americans, and millions of people globally. Those numbers would be even higher without medical breakthroughs. Let's talk about some of them. In 1996, Highly Active Antiretroviral Therapy (HAART) was developed. It suppresses the virus from replicating and attacking your immune system, which lowers your viral load and increases the CD4 (white blood cells that fight infections for your immune system). That reduces your risk of opportunistic infections and extends your life expectancy. The decrease in viral load makes HIV less transmissible and helps reconstitute your immune system, but it took a while before it was known by how much This was a major breakthrough in HIV treatment and prevention. But it was hardly the first. Perhaps the first big break came in 1983, when scientists isolated the virus that pinpointed the cause of AIDS. This revolutionized the understanding of AIDS — where it was, how it works, and how to combat it. Then in 1985, the first HIV blood test was licensed. This was a breakthrough of sorts, because it allowed the virus to be detected before it was too late. But there was still no treatment. That came in 1987 when AZT was developed. AZT was the first antiretroviral treatment for HIV-AIDS. It helped and prevented mother-to-child transmission of the virus. But it had serious side effects. I've heard horrible stories from AZT survivors, but it was all that was available at the 1996, when HAART changed everything. By 1997, it was the standard of care for new HIV cases. In 2012, it was discovered that providing HIV medication to HIV-negative people at high risk for the virus could prevent transmission, with an incredible success rate. This is called pre-exposure prophylaxis or PrEP. It was meant to be another amazing breakthrough in science. For the first time, there was a proven method of preventing HIV transmission. The implications included ending transmission of HIV, and ending the HIV-AIDS epidemic. But PrEP hasn't been widely accepted by the public, mostly due to stigma associated with HIV and LGBTQ people. So we're yet to achieve those goals. The year 2016 changed my life more than any other. I was at a conference in Florida where Bruce Richman spoke about U=U. It played a huge role in my decision to become an HIV advocate. I've been an ambassador for U=U ever since. What is U=U? Undetectable equals Untransmittable means that when you take HIV medication as prescribed, you can achieve an undetectable viral load. This means there's not enough virus in your blood to be counted. What happens to the virus? Small amounts of it can survive but remain harmlessly dormant in your body, in small amounts known as reservoirs. The virus can't be transmitted sexually or mother to child. People who live with HIV can safely have children with no risk of transmission to their partner or baby. This revelation was monumental and it's changed lives. It was a breakthrough in understanding. In 2021, there came the first long-acting injectable. It was a breakthrough for those who struggled with pill fatigue or forgetfulness. Pill fatigue is a common problem, especially because there's also stigma associated with simply taking meds for HIV. I remember learning about injectable HIV medication at a conference called CROI (Conference on Retroviruses and Opportunistic Infections). It's a scientific event that attracts leading experts who discuss research and findings for collective understanding. I've attended the conference twice as a community liaison and learned so much about HIV research and the experts doing it. I learned about the potential for longer acting treatments, and about research exploring different methods of delivery, from injectable treatments to the possibility of implants. I can tell you that even a few years ago, research for a cure of HIV-AIDS was getting really exciting. I truly believe we're close to finding a cure. Now is not the time to kill funding dedicated to this research. I've talked about a lot of breakthroughs in HIV. This year, that list of breakthroughs adds another big advancement. In 2025 the FDA approved a drug that can be injected twice yearly, once every 6 months. It can also be used as PrEP, which has also been approved. That's incredible! You don't have to remember to take meds every day, carry meds with you, or be seen taking them. I hold on to hope that one day one of these breakthroughs will change public perception of HIV. There's no reason to fear this virus as long as you have access to the medicine. The stigma of HIV is antiquated. It's based on a mysterious disease that was a certain death sentence and only affects gay men But none of this is true anymore. HIV is no longer the deadly disease it once was. With incredible advancements, there's no excuse for fear or stigma to exist. HIV today is nothing more than a chronic condition that's easily managed, and only getting better with time. I believe we're close to a cure. I just learned that researchers have found a way to awaken dormant HIV cells. I find that extremely exciting and wonder if it could lead to a cure. If dormant cells can be awakened, then targeted and killed, that could be a cure. It's so exciting that we're getting closer, so it's no time for defunding HIV research and prevention efforts.
